Compare State Street SPDR S&P Biotech ETF (XBI) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B), while Direxion Daily FTSE China Bull 3x Shares trades at $25.27 (market cap $560.32M). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 18× Direxion Daily FTSE China Bull 3x Shares's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR S&P Biotech ETF for 38 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| XBI | YINN | |
|---|---|---|
Market Cap | $10.11B | $560.32M |
Volume | 12,903,266 | 1,009,521 |
Sector | Broad Market / Factor | Leveraged / Inverse |
52-Week High | $169.55 | $52.69 |
52-Week Low | $104.99 | $21.45 |
Typical Hold Time | 38 Days | 25 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
YINN trades at $23.63, up 0.3% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. Moving averages indicate strong bearish momentum while oscillators remain neutral. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific fundamentals show limited available data.
The bearish technical setup and lack of clear fundamental metrics create uncertainty. Investment opportunity depends on broader market trends and China's economic developments, while risks include technical breakdown below support and regional economic volatility. Further fundamental disclosure is needed for comprehensive analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
